Adeno-Associated Virus (AAV) Versus Immune Response
AbstractDecades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them. View Full-Text
Share & Cite This Article
Rabinowitz, J.; Chan, Y.K.; Samulski, R.J. Adeno-Associated Virus (AAV) Versus Immune Response. Viruses 2019, 11, 102.
Rabinowitz J, Chan YK, Samulski RJ. Adeno-Associated Virus (AAV) Versus Immune Response. Viruses. 2019; 11(2):102.Chicago/Turabian Style
Rabinowitz, Joseph; Chan, Ying K.; Samulski, Richard J. 2019. "Adeno-Associated Virus (AAV) Versus Immune Response." Viruses 11, no. 2: 102.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.